Edwards Lifesciences Q2 FY25: where the revenue came from and where it went
The whole income statement of Edwards Lifesciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2025
- Reported
- Aug 6, 2025
Revenue$1.53B
+12% year over year
Gross profit$1.19B
78% margin
Operating profit$0.41B
27% margin
Net profit$0.33B
22% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.53 | 100% | +12% |
| Aortic valve replacement | 1.13 | 74% | +9% |
| Surgical heart valve therapy | 0.27 | 17% | +8% |
| Transcatheter mitral | 0.14 | 9% | +62% |
| Cost of revenue | −0.34 | 22% | |
| Gross profit | 1.19 | 78% margin | −2pp |
| R&D | −0.28 | 18% | −2pp |
| SG&A | −0.50 | 33% | +0pp |
| Operating profit | 0.41 | 27% margin | +0pp |
| Interest & other costs | −0.01 | ||
| Tax | −0.06 | ||
| Net profit | 0.33 | 22% margin | −5pp |
154 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest